In This Article:
-
Mpox remains a global public health crisis in 2025, with Clade 1b exhibiting higher transmissibility and severity than Clade 2.
-
The Democratic Republic of the Congo (DRC) is the epicenter, with over 60,000 suspected cases and 1,300 deaths in 2024 alone.
-
The virus has now spread to multiple countries, including the U.S., Canada, and Europe, raising concerns about global containment.
-
The U.S. has confirmed four Clade 1b cases (California, Georgia, New Hampshire, and New York), prompting the need for urgent action.
-
The current vaccine supply chain is inadequate, relying heavily on a single non-U.S. manufacturer.
-
Delays in vaccine distribution, high costs, and limited production capacity have exacerbated the crisis, particularly in Africa, where vaccine stockpiles remain largely unused due to logistical and political challenges.
-
GEO-MVA, the GeoVax Mpox vaccine candidate is advancing to clinical evaluation, anticipated for H2 '25.
ATLANTA, GA - March 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announces that Chairman & CEO, David Dodd will present at Tribe Public's CEO Presentation and Q&A Webinar Event titled "MPOX 2025: Navigating the Global Public Health Emergency." The Event is scheduled to begin at 8:30am Pacific/11:30am Eastern on Thursday, March 6, 2025.
To register to join the complimentary, ZOOM webinar-based event, please visit MPOX-EMERGENCY.TribePublic.com. Once registered, participants may begin forwarding their questions for GeoVax's management to Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin(R) combined with an immune checkpoint inhibitor is planned. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.